Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Annatto Tocotrienol, Vitamin D & Resveratrol May Offer Blood Sugar Benefits, Reduce Inflammation - Nutraceuticals World

What are you searching for?

Sign in
Market Updates, Products & Ingredients, Research

Annatto Tocotrienol, Vitamin D & Resveratrol May Offer Blood Sugar Benefits, Reduce Inflammation

Type 2 diabetes patients taking 500 mg/day of delta-tocotrienol for 24 weeks saw improved glycemic control along with reduced inflammation and oxidative stress.

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Delta-tocotrienol from annatto alone or in combination with other dietary ingredients improved glycemic control and inflammation, according to a clinical study in patients with type 2 diabetes mellitus. Results were published in the Journal of Diabetes and Clinical Studies.
 
Results of the randomized, double-blind, placebo-controlled trial of the patented DeltaGold annatto-derived tocotrienol ingredient by American River Nutrition, with or without vitamin D3 and resveratrol, indicate significant efficacy on fasting blood glucose, glycated hemoglobin (HbA1c), insulin, HOMA-IR scores, and various inflammation and oxidative stress markers.
 
In the 24-week study of 120 type 2 diabetes patients, delta-tocotrienol (from DeltaGold)—administered at a dosage of 500 mg/day—was compared to vitamin D3 and resveratrol, all of which led to improved glycemic control accompanied by reduced inflammation and oxidative stress. This study was blinded and compared to a placebo group. In a separate 24-week study of 112 type 2 diabetes patients, a combination of 250 mg delta-tocotrienol, 250 mg resveratrol, and 5,000 IU vitamin D3 were tested against placebo for the same parameters, with similar or slightly improved beneficial results.
 
Study Details
In the 24-week trial studying individual components, delta-tocotrienol was more effective than vitamin D3 and resveratrol in all parameters measured (except IL-6), and efficiently improved glucose control while reducing inflammation and oxidative stress. HbA1c, a long-term stable measure of blood sugar control, was successfully reduced from 8.4% to 7.8 without change in the placebo group. In addition to improved glucose control, researchers found that inflammation, marked by high-sensitivity C-reactive protein (hs-CRP), was reduced by 12%, while TNF-alpha dropped by 14%. Oxidative stress was also lowered significantly, with biomarker malondialdehyde (MDA) dropping by 11% without change in the placebo group.
 
Blood sugar management was supported by significant reductions in fasting blood glucose (7%), insulin (9%), and the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR; 14%) for patients taking annatto tocotrienols, while these biomarkers remained largely unchanged in the placebo group.
 
As a first, this trial showed that of all the groups studied, delta-tocotrienol had the strongest effect on adhesion molecules, reducing markers such as VCAM-1 and ICAM-1 by 55-75%.
 
A combination of delta-tocotrienol, vitamin D3 and resveratrol, studied in a separate 24-week trial, performed >20% better than delta-tocotrienol alone, improving glycemic control by decreasing HbA1c, HOMA-IR and insulin 10-20%, and lowering inflammation markers by 20-25%.
 
“The huge amount of data in favor of delta-tocotrienol as well as its combination with vitamin D3 and resveratrol further cements the newly-found glycemic control benefits of the supplement,” said Dr. Barrie Tan, president of American River Nutrition. “What’s new about this study is that it confirms delta-tocotrienol’s superior anti-velcro effect, which had previously only been shown in animal studies. Delta-tocotrienol’s ability to cause a steep reduction in adhesion molecules suggests potential management of atherosclerosis in addition to a tight glycemic control.”

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics